

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT2967242

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
APPLERA CORPORATION	10/09/2007
RECEIVING PARTY DATA	
Name:	ASURAGEN, INC.
Street Address:	2150 WOODWARD STREET
Internal Address:	SUITE 100
City:	AUSTIN
State/Country:	TEXAS
Postal Code:	78744
PROPERTY NUMBERS Total: 3	
Property Type	Number
Patent Number:	8568971
Patent Number:	8465914
Application Number:	14062612
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	ben.horton@nortonrosefulbright.com
Correspondent Name:	FULBRIGHT & JAWORSKI LLP
Address Line 1:	98 SAN JACINTO BOULEVARD
Address Line 2:	SUITE 1100
Address Line 4:	AUSTIN, TEXAS 78701
ATTORNEY DOCKET NUMBER:	ASUR.P0007US.D1
NAME OF SUBMITTER:	BEN HORTON
SIGNATURE:	/Ben Horton/
DATE SIGNED:	08/04/2014
Total Attachments: 3	
source=3_APPLERA-ASURAGEN#page1.tif	
source=3_APPLERA-ASURAGEN#page2.tif	
source=3_APPLERA-ASURAGEN#page3.tif	

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT (this "Assignment") is made and entered into as of March 2, 2006 (the "Effective Date") by and between Applera Corporation, a Delaware corporation, through its Applied Biosystems Group with offices at 850 Lincoln Centre Drive, Foster City, CA 94404 ("Assignor"), and Asuragen, Inc., a Delaware corporation, with its principal office at 2150 Woodward Street, Suite 100, Austin, TX 78744 ("Assignee").

WHEREAS, Assignor and Assignee are parties to a certain Cross License and Co-Existence Agreement dated March 2, 2006 (the "Agreement"); and


WHEREAS, pursuant to the Agreement, Assignor wishes to assign to Assignee, and Assignee wishes to acquire from Assignor, all right, title and interest in and to (1) the United States patents set forth on Schedule A hereto, which are conveyed together with all rights to sue for past or future infringements, (2) the United States patent applications set forth on Schedule B hereto, and all patents issuing from such applications, (3) the Patent Cooperation Treaty applications set forth on Schedule C hereto, and all foreign counterparts issuing from such applications, and all United States and foreign patents and patent applications, not otherwise identified above, that disclose and claim any of the inventions identified in Schedules A, B and C hereto, and (4) all continuation, divisional, continuation-in-part, reissue, reexamination and extension applications filed in the United States and in any foreign country that claim priority to or from or have identical disclosure as any one of more of the United States and foreign patents, patent applications, or inventions identified in (1), (2), and/or (3) above, and all intellectual property rights issuing or resulting therefrom (collectively referred to herein as the "Patents").

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby sells, assigns, transfers and sets over to Assignee the entire right, title and interest in and to the Patents, for the United States and for all foreign countries, including without limitation any and all other corresponding rights that are or may be secured under the laws of the United States and any foreign country, now or hereafter in effect, for Assignee's own use and enjoyment, and for the use and enjoyment of Assignee's successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made, together with all income, royalties, damages or payments due or payable as of the Effective Date or thereafter, including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Patents, with the right to sue for, and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, assigns, or other legal representatives.

Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks, and the corresponding entities or agencies in any applicable foreign countries, to record Assignee as the assignee and owner of the Patents. To the extent reasonably necessary, Assignor will undertake all acts to assist Assignee in recording or otherwise establishing its rights as owner of the Patents and Applications listed on the Exhibits hereto.

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed by its duly authorized representatives as of the Effective Date above written.

Applera Corporation, through its Applied Biosystems Group




Name: John W. Burns, Ph.D., Esq.

Title: Director, Ambion Legal

STATE OF TEXAS §
 §
COUNTY OF TRAVIS §

This instrument was acknowledged before me on October 9th, 2007 by John W. Burns, an individual acting on behalf of Applera Corporation, through its Applied Biosystems Group.



Notary Public in and for the State of Texas
My Commission Expires: 2-18-2008



**SCHEDULE A
UNITED STATES PATENTS**

US Patent #	Issue Date	Title
5,677,124	10/14/97	Ribonuclease Resistant Viral RNA Standards
5,919,625	07/06/99	Ribonuclease Resistant Viral RNA Standards
5,939,262	08/17/99	Ribonuclease Resistant RNA Preparation and Utilization
6,399,307	06/04/02	Methods of Quantifying Viral Load in an Animal with a Ribonuclease Resistant RNA Preparation
7,033,749	04/25/06	Ribonuclease Resistant RNA Preparation and Utilization

**SCHEDULE B
UNITED STATES PATENT APPLICATIONS**

Application #	Filing Date	Title
60/021,145	07/03/96	Method for Large Scale RNA Synthesis And Purification
60/265,692	01/31/01	Comparative Competitive Amplification of Fractionated Targets from Multiple Nucleic Acid Samples
60/265,694	01/31/01	Comparative analysis of nucleic acids using population tagging
60/575,743	05/28/04	Methods and compositions involving MicroRNA
60/627,171	11/02/04	Methods and Compositions Involving modified MiRNA molecules and MiRNA Inhibitor Molecules
60/649,584	02/03/05	Methods and compositions involving microRNA
60/649,634	02/03/05	Methods and Compositions Involving modified MiRNA molecules and MiRNA Inhibitor Molecules
60/683,736	05/23/05	Methods and Compositions Involving modified MiRNA molecules and MiRNA Inhibitor Molecules
10/632,539	07/31/03	Comparative Analysis of Nucleic Acids Using Population Tagging
10/632,534	07/31/03	Competitive Amplification of Fractionated Targets from Multiple Nucleic Acid Samples
10/880,350	06/29/04	Methods and compositions for preparing capped RNA
10/883,186	07/01/04	System and Method for Processing Results of a Complex Genetic Test
10/963,415	10/12/04	Methods and compositions for analyzing nucleic acids
11/141,707	05/31/05	Methods and compositions involving microRNA
11/273,640	11/14/05	Methods and Compositions Involving MiRNA and MiRNA

**SCHEDULE C
PATENT COOPERATION TREATY APPLICATIONS**

Serial No.	Filed	Title
PCT/US97/12551	07/02/97	Ribonuclease Resistant RNA Preparation and Utilization - CIP
PCT/US05/22710	06/28/05	Methods and Compositions for Preparing Capped RNA
PCT/US05/18826	05/31/05	Methods and Compositions Involving MicroRNA
PCT/US05/36799	10/12/05	Methods and Compositions for Analyzing Ribonucleic Acids (Amended)
PCT/US05/41162	11/14/05	Methods and Compositions Involving Modified MiRNA Molecules And MiRNA Inhibitor Molecules
PCT/US02/03097	01/30/02	Comparative Analysis of Nucleic Acids Using Population Tagging
PCT/US02/03169	01/30/02	Competitive Amplification of Fractionated Targets from Multiple Nucleic Acid Samples
PCT/US05/23348	07/01/05	System and Method for Processing Results of a Complex Genetic Test

RECORDED: 10/15/2007

PATENT
REEL: 019965 FRAME: 0102

RECORDED: 08/04/2014

PATENT
REEL: 033458 FRAME: 0321